Fruquintinib - HUTCHMED
Alternative Names: Aiyoute; Elunate; FRUZAQLA; HMPL-013; TAK-113Latest Information Update: 27 Sep 2024
At a glance
- Originator Hutchison MediPharma
- Developer BeiGene; Eli Lilly and Company; Genor Biopharma; Hutchison MediPharma; HUTCHMED; Shanghai Junshi Biosciences
- Class Antineoplastics; Benzofurans; Quinazolines; Small molecules
- Mechanism of Action Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Colorectal cancer
- Preregistration Endometrial cancer
- Phase III Non-small cell lung cancer
- Phase II/III Renal cell carcinoma
- Phase II Solid tumours
- Phase I/II Triple negative breast cancer
- Preregistration Submission Withdrawal Gastric cancer
Most Recent Events
- 24 Sep 2024 Registered for Colorectal cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in Japan (PO)
- 20 Sep 2024 Registered for Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom (PO)
- 10 Sep 2024 Registered for Colorectal cancer (Second-line therapy or greater, Metastatic disease) in Canada (PO) ;